Lutalo PM, D'Cruz DP, et al.
International immunopharmacology. Date of publication 2015 Aug 1;volume 27(2):209-12.
1. Int Immunopharmacol. 2015 Aug;27(2):209-12. doi: 10.1016/j.intimp.2015.04.023.
Epub 2015 Apr 20.
Biological drugs in ANCA-associated vasculitis.
Lutalo PM(1), D'Cruz DP(2).
Author information:
(1)Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, Guy's
Hospital, Great Maze Pond, London SE1 9RT, United Kingdom. Electronic address:
pamela.lutalo@kcl.ac.uk.
(2)Louise Coote Lupus Unit, Guy's and St Thomas' NHS Foundation Trust, Guy's
Hospital, Great Maze Pond, London SE1 9RT, United Kingdom. Electronic address:
david.dcruz@kcl.ac.uk.
The anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitides
granulomatosis with polyangiitis (GPA), eosinophilic granulomatosis with
polyangiitis (EGPA) and microscopic polyangiitis (MPA) constitute a wide spectrum
of clinical manifestations of systemic vasculitis which may range from limited
disease to organ or life-threatening disease. The introduction of biologics for
the management of severe ANCA-associated vasculitis and severe, relapsing disease
refractory to conventional immunosuppressants, has significantly improved the
clinical prognosis of these autoimmune disorders. Rituximab, an anti-CD20
monoclonal antibody is licenced for remission induction in severe GPA and MPA and
the management of severe relapsing, refractory GPA and MPA. Belimumab, an anti-B
lymphocyte stimulatory monoclonal antibody is in clinical trials for the
management of the ANCA-associated vasculitis GPA. Mepolizumab and Omalizumab are
biologics which have been reported to be efficacious in refractory asthma
associated with EGPA. The role of anti-TNF therapy and T cell targeting drugs in
ANCA-associated vasculitis is less clear due to limited study data. This review
will summarise the clinical trials and clinical practice use of biologic
treatment strategies for the management of ANCA-associated vasculitis.
Copyright © 2015 Elsevier B.V. All rights reserved.
DOI: 10.1016/j.intimp.2015.04.023
PMID: 25907243 [Indexed for MEDLINE]
